CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 691703-691855 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/2008f024274c53b0de1276f4047a6a641813fd98","sourcedb":"CORD-19","sourceid":"2008f024274c53b0de1276f4047a6a641813fd98","text":"Sensitivity analyses showed that TEL/AMC/LEV had superior health outcomes even when only 5% of in vitro resistant organisms were also resistant in vivo.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"T98989","span":{"begin":0,"end":152},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T98989","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T131","span":{"begin":0,"end":152},"obj":"Sentence"}],"attributes":[{"subj":"T131","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T6356","span":{"begin":37,"end":40},"obj":"Disease"}],"attributes":[{"id":"A6356","pred":"mondo_id","subj":"T6356","obj":"http://purl.obolibrary.org/obo/MONDO_0015168"},{"subj":"T6356","pred":"source","obj":"CORD-19-PD-MONDO"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#93b1ec","default":true},{"id":"CORD-19_Custom_license_subset","color":"#cbec93"},{"id":"CORD-19-PD-MONDO","color":"#ec93e5"}]}]}}